Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Abaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein (PTHrP 1-34). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis in postmenopausal women at high fracture risk. Like the related teriparatide, studies describe it as stimulating new bone formation, but it exhibits a distinct receptor-binding profile.
Researched for
Postmenopausal osteoporosisReduction of fracture risk in high-risk individualsIncrease in bone mineral density
Official status
US: Prescription
In the United States, abaloparatide (brand name Tymlos) has been FDA-approved since April 2017 as a prescription medicine for the treatment of osteoporosis in postmenopausal women at high fracture risk.
Abaloparatide is a synthetic analogue of the first 34 amino acids of parathyroid hormone-related protein (PTHrP). Like parathyroid hormone and teriparatide it binds the PTH-1 receptor, but the literature describes it as preferentially engaging the so-called RG conformation of the receptor, which is associated with shorter signaling duration. As for the entire drug class, intermittent receptor activation is regarded as the mechanistic basis for the stimulation of bone-forming osteoblasts observed in studies, whereas continuously elevated exposure would tend to favor bone resorption. From this binding behavior the literature derives a discussed balance between bone formation and bone resorption.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · single evidence tier
Human RCT
4
03
What the studies show
Human RCT
Mensch
Miller PD, Hattersley G, Riis BJ, et al. 2016
Reduction in the incidence of new vertebral fractures in postmenopausal women with osteoporosis compared with placebo.
What does NOT follow: Observed in a randomized, placebo- and active-controlled registration trial in a defined population of postmenopausal women with osteoporosis; not generalizable to other populations or routes of administration.
Human RCT
Mensch
Miller PD, Hattersley G, Riis BJ, et al. 2016
Reduction in the incidence of nonvertebral and major osteoporotic fractures versus placebo over the study period.
What does NOT follow: Secondary endpoints of a single registration trial over a limited observation period; effect size is context-dependent and not transferable to individuals.
Human RCT
Mensch
Miller PD, Hattersley G, Riis BJ, et al. 2016
Increase in bone mineral density at the lumbar spine, total hip, and femoral neck relative to baseline in clinical trials.
What does NOT follow: Bone mineral density is a surrogate marker; changes do not necessarily equate to clinical benefit in every individual and were measured under trial conditions.
Human RCT
Mensch
Leder BZ, Zapalowski C, Hu MY, et al. 2019
Sustained fracture-risk reduction when the anabolic phase was followed by an antiresorptive sequential treatment.
What does NOT follow: Result of an extension study with sequential therapy; reflects a combined treatment course and is not transferable to the single agent alone or to individuals.
04
Where studies disagree
Open question
Is the osteosarcoma warning of bone-building agents clinically relevant for abaloparatide too?
POSITION A
Like teriparatide, abaloparatide carried an osteosarcoma warning due to rat findings and was subject to a time limit.
POSITION B
The US regulator later removed the osteosarcoma boxed warning, as the risk did not materialise in humans.
CURRENT STATE · Human data relieved the original rat-based warning; anabolic therapy nonetheless remains time-limited.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 1.7 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
In approved use and in clinical trials, abaloparatide is administered subcutaneously. This statement describes the documented trial and approval context and does not constitute a usage instruction.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Adverse events reported in clinical trials include, among others, dizziness, nausea, headache, palpitations, fatigue, as well as transient injection-site reactions and a transient increase in calcium.
Frequency and severity are derived from controlled trial populations and cannot be directly extrapolated to individuals.
Animal model
In preclinical studies in rats, an increased occurrence of osteosarcoma was observed under high, long-duration exposure, which historically led to a regulatory warning for the entire drug class.
Finding from an animal model with high exposure; its relevance to humans is a subject of expert discussion and is contextualized in the regulatory labeling.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Abaloparatide is often compared directly with teriparatide (Forteo) in osteoporosis communities — regarding tolerability, the daily injection and pen handling.
recurring direct comparison
Not supported by studies: Subjective comparisons do not replace a controlled head-to-head; both are anabolic osteoporosis agents with limited treatment duration. Individual tolerability varies widely.
10b
What online communities discuss
Recurring themes from Reddit, Quora and patient forums — synthetically summarised, sources linked. Not scientific evidence, but a signal of what users report. Deliberately separated from the study base.
Non-scientific sources. What users report in forums — synthetically summarised, paraphrased, with link to source. Not validated by studies.
Sorted by discussion frequency · 1 Thema
Discussion frequency: ~134 aggregated reviews
On drugs.com, abaloparatide (Tymlos) holds an average user rating of about 5.2 out of 10 across roughly 134 reviews (about 30% positive, 34% negative). Commonly named are back pain, nausea, headache, heart palpitations and fatigue; positive reports highlight gains in bone density.
What this does NOT mean:Review platforms are self-selected, unblinded and not representative; the figures are a snapshot (as of June 2026). They do not replace controlled data — see the studies section. Like teriparatide, abaloparatide is a bone-building (anabolic) agent with time-limited use; the rating spread is wide.
In the United States, abaloparatide (brand name Tymlos) has been FDA-approved since April 2017 as a prescription medicine for the treatment of osteoporosis in postmenopausal women at high fracture risk.
2026-06-07
Germany
Prescription
In Germany, abaloparatide is available as a prescription medicine via the centralized EU authorization. Historically, the first marketing application was refused by the EMA in 2018; following a resubmission with supplementary data, the European Commission granted marketing authorization in December 2022 under the name Eladynos for the treatment of osteoporosis in postmenopausal women at increased fracture risk.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial